(Q43161894)

15 November 2017

Spotlight on cerebrolysin in dementia (English)

1 reference

15 November 2017

1

Greg L Plosker

1 reference

15 November 2017

Serge Gauthier

2

1 reference

15 November 2017

1 March 2010

1 reference

15 November 2017

1 reference

15 November 2017

24

1 reference

15 November 2017

263-266

1 reference

15 November 2017

3

1 reference

https://scigraph.springernature.com/pub.10.2165/11204820-000000000-00000

15 November 2017

0 references

cites work

A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11204820-000000000-00000

Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons

21 January 2018

1 reference

12 December 2020

Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.

1 reference

12 December 2020

A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.

1 reference

12 December 2020

Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis.

1 reference

12 December 2020

The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease.

1 reference

12 December 2020

Therapeutic results with Cerebrolysin in the treatment of dementia.

1 reference

12 December 2020

Sustained improvement of cognition and global function in patients with moderately severe Alzheimer's disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin.

1 reference

12 December 2020

Effects of NGF, b-FGF, and cerebrolysin on water maze performance and on motor activity of rats: short- and long-term study.

1 reference

12 December 2020

Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity

1 reference

12 December 2020

The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance.

1 reference

12 December 2020

A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease.

1 reference

12 December 2020

The influence of Cerebrolysin and E021 on spatial navigation of 24-month-old rats.

1 reference

12 December 2020

A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration

1 reference

12 December 2020

Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT).

1 reference

12 December 2020

Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease.

1 reference

12 December 2020

The short-term influence of b-FGF, NGF and Cerebrolysin on the memory impaired after fimbria-fornix lesion.

1 reference

12 December 2020

Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice.

1 reference

12 December 2020

Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain

1 reference

12 December 2020

[Mild forms of multi-infarct dementia: effectiveness of cerebrolysin].

1 reference

12 December 2020

Ameliorative influence of a nootropic drug on motor activity of rats after bilateral carotid artery occlusion.

1 reference

12 December 2020

Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.

1 reference

12 December 2020

Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin

1 reference

12 December 2020

Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin

1 reference

12 December 2020

Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease

1 reference

12 December 2020

The long-term effect of NGF, b-FGF and Cerebrolysin on the spatial memory after fimbria-fornix lesion in rats.

1 reference

12 December 2020

Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin.

1 reference

12 December 2020

Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection

1 reference

12 December 2020

10.2165/11204820-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

20155999

Dimensions Publication ID

15 November 2017

0 references

1 reference

PubMed ID

20155999